Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est
Xeris Biopharma Holdings (NASDAQ: XERS ) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.